Sanford C. Bernstein Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by Sanford C. Bernstein from $753.00 to $781.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently issued reports on REGN. Morgan Stanley reaffirmed an “overweight” rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating for the company in a research note on Monday, June 9th. Canaccord Genuity Group reissued a “buy” rating and set a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $586.96 on Wednesday. The company has a 50 day moving average of $554.52 and a 200-day moving average of $589.43. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $1,210.97. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The company has a market cap of $62.21 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 1.96 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $11.56 EPS. As a group, equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 8.87%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Pinney & Scofield Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. increased its position in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.